Lv5
1010 积分 2025-02-27 加入
Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death
1个月前
已完结
Current situation of zalutumumab
6个月前
已完结
ERBB receptors and cancer: the complexity of targeted inhibitors
9个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
9个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
10个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
10个月前
已完结
Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study
10个月前
已完结
Major Strides in HER2 Blockade for Metastatic Breast Cancer
11个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
11个月前
已完结